VENTAC PARTNERS IS A DEDICATED LIFE SCIENCE CONSULTING FIRM WITH OFFICES IN EUROPE, USA AND ASIA.

Ventac Partners has a strong track record in founding new innovative companies, strategic and operational market and product analysis, intellectual property development, fund raising, licensing, M&A and strategy consulting.

All partners are experienced executives from pharma, biotech and medtech companies, and preclinical, clinical and regulatory, legal and intellectual property experts with extensive backgrounds in successfully starting, growing and expanding international life science companies.

Latest News
April, 2013 | Ventac Partners and Norwegian University of Science and Technology (NTNU) celebrate 10-year anniversary, see VP News.

February, 2013 | A Board of Swiss investors selects Zestagen as #1 biotech company to invest in on behalf of the prestigious Swiss economic review BILAN.

November, 2012 | Avexxin, a company focusing on the development of novel anti-inflammatory drugs, announces completion of a Series B Round Financing.

November, 2012 | Ventac Partners announces foundation of a novel cancer company in the United Kingdom, see Portfolio News.

Newsblitz

Avexxin receives regulatory approval to begin clinical trial testing of its anti-psoriasis compound AVX-001.

More Information

VENTAC PARTNERS IS A DEDICATED LIFE SCIENCE CONSULTING FIRM WITH OFFICES IN EUROPE, USA AND ASIA.

Ventac Partners has a strong track record in founding new innovative companies, strategic and operational market and product analysis, intellectual property development, fund raising, licensing, M&A and strategy consulting.

All partners are experienced executives from pharma, biotech and medtech companies, and preclinical, clinical and regulatory, legal and intellectual property experts with extensive backgrounds in successfully starting, growing and expanding international life science companies.

Content on this page requires a newer version of Adobe Flash Player.